Wing-Lok Chan1, Yuen-Hung Tricia Ho1, Carlos King-Ho Wong2,3, Horace Cheuk-Wai Choi4, Ka-On Lam1, Kwok-Keung Yuen4, Dora Kwong1, Ivan Hung5. 1. Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 2. Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 3. Department of Family Medicine and Primary Care, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 4. Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China. 5. Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Abstract
Emerging efficacy and safety data have led to the authorization of COVID-19 vaccines worldwide, but most trials excluded patients with active malignancies. This study evaluates the intended acceptance of COVID-19 vaccination in cancer patients in Hong Kong. METHODS: 660 adult cancer patients received a survey, in paper or electronic format, between 31 January 2021 and 15 February 2021. The survey included patient's clinical characteristics, perceptions of COVID-19 and vaccination, vaccine knowledge, cancer health literacy, and Hospital Anxiety and Depression scale (HADS). The primary outcome was the intended acceptance of COVID-19 vaccine in cancer patients. Multivariable analysis was performed to identify factors associated with intended acceptance. RESULTS: The intended acceptance of COVID-19 vaccination was 17.9%. A total of 487 (73.8%) believed that vaccination could prevent them from infection. Over 70% worried about vaccine negative effects on cancer and its side effects. Factors associated with intended acceptance included higher level of "belief in vaccine on preventing them from getting COVID-19", less worry about long-term side effects of vaccine, lower level of cancer health literacy, and normal HADS (Depression scale). CONCLUSIONS: To improve vaccine acceptance rate, public education campaigns specific to cancer patients to gain their trust in efficacy and relieve their worries are needed.
Emerging efficacy and safety data have led to the authorization of COVID-19 vaccines worldwide, but most trials excluded patients with active malignancies. This study evaluates the intended acceptance of COVID-19 vaccination in cancerpatients in Hong Kong. METHODS: 660 adult cancerpatients received a survey, in paper or electronic format, between 31 January 2021 and 15 February 2021. The survey included patient's clinical characteristics, perceptions of COVID-19 and vaccination, vaccine knowledge, cancer health literacy, and Hospital Anxiety and Depression scale (HADS). The primary outcome was the intended acceptance of COVID-19 vaccine in cancerpatients. Multivariable analysis was performed to identify factors associated with intended acceptance. RESULTS: The intended acceptance of COVID-19 vaccination was 17.9%. A total of 487 (73.8%) believed that vaccination could prevent them from infection. Over 70% worried about vaccine negative effects on cancer and its side effects. Factors associated with intended acceptance included higher level of "belief in vaccine on preventing them from getting COVID-19", less worry about long-term side effects of vaccine, lower level of cancer health literacy, and normal HADS (Depression scale). CONCLUSIONS: To improve vaccine acceptance rate, public education campaigns specific to cancerpatients to gain their trust in efficacy and relieve their worries are needed.
Authors: Wei Kang; Jessica J P Shami; Vincent K C Yan; Xuxiao Ye; Joseph E Blais; Xue Li; Victor H F Lee; Celine S L Chui; Francisco T T Lai; Eric Y F Wan; Carlos K H Wong; Ian C K Wong; Esther W Chan Journal: J Hematol Oncol Date: 2022-05-19 Impact factor: 23.168
Authors: Daphne Day; Lisa Grech; Mike Nguyen; Nathan Bain; Alastair Kwok; Sam Harris; Hieu Chau; Bryan Chan; Richard Blennerhassett; Louise Nott; Nada Hamad; Annette Tognela; David Hoffman; Amelia McCartney; Kate Webber; Jennifer Wong; Craig Underhill; Brett Sillars; Antony Winkel; Mark Savage; Bao Sheng Loe; Daniel Freeman; Eva Segelov Journal: Vaccines (Basel) Date: 2022-05-26
Authors: Maria João de Sousa; Cecília Caramujo; Neidy Júlio; Joana Correia Magalhães; Raquel Basto; Teresa Fraga; Inês Ferreira Gomes; Ana Raquel Monteiro; Isabel Pazos; Gabriela Sousa Journal: Support Care Cancer Date: 2022-02-04 Impact factor: 3.359